AmirAli Talasaz

4.3k total citations · 2 hit papers
106 papers, 2.3k citations indexed

About

AmirAli Talasaz is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, AmirAli Talasaz has authored 106 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Cancer Research, 42 papers in Pulmonary and Respiratory Medicine and 40 papers in Oncology. Recurrent topics in AmirAli Talasaz's work include Cancer Genomics and Diagnostics (83 papers), Genetic factors in colorectal cancer (31 papers) and Lung Cancer Treatments and Mutations (27 papers). AmirAli Talasaz is often cited by papers focused on Cancer Genomics and Diagnostics (83 papers), Genetic factors in colorectal cancer (31 papers) and Lung Cancer Treatments and Mutations (27 papers). AmirAli Talasaz collaborates with scholars based in United States, South Korea and Canada. AmirAli Talasaz's co-authors include Richard B. Lanman, Kimberly C. Banks, Darya Chudova, Ronald W. Davis, Oliver A. Zill, Stefanie Mortimer, Rebecca J. Nagy, Helmy Eltoukhy, Justin I. Odegaard and Razelle Kurzrock and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

AmirAli Talasaz

95 papers receiving 2.3k citations

Hit Papers

The Landscape of Actionab... 2018 2026 2020 2023 2018 2024 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
    2018 271 citations Oliver A. Zill, Kimberly C. Banks et al. Clinical Cancer Research profile →
  2. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening
    2024 163 citations Victoria M. Raymond, Craig Eagle et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
AmirAli Talasaz United States 17 1.5k 1.2k 900 625 501 106 2.3k
Giulia Siravegna Italy 22 1.9k 1.3× 1.6k 1.3× 1.1k 1.2× 1.4k 2.3× 621 1.2× 42 3.3k
Javier García-Corbacho Spain 15 1.5k 1.0× 1.1k 0.9× 800 0.9× 887 1.4× 395 0.8× 44 2.3k
Petros Nikolinakos United States 20 869 0.6× 1.5k 1.3× 986 1.1× 628 1.0× 338 0.7× 51 2.4k
Jonathan C. M. Wan United Kingdom 10 1.5k 1.0× 681 0.6× 656 0.7× 836 1.3× 357 0.7× 23 2.0k
Kert D. Sabbath United States 12 1.2k 0.8× 1.9k 1.6× 541 0.6× 544 0.9× 225 0.4× 26 2.7k
Evelyne Lopez‐Crapez France 26 989 0.7× 1.3k 1.1× 501 0.6× 927 1.5× 524 1.0× 68 2.4k
Peter Ulz Austria 22 2.0k 1.3× 1.1k 1.0× 923 1.0× 1.1k 1.7× 476 1.0× 35 2.7k
Betania Mahler‐Araujo United Kingdom 10 1.6k 1.0× 973 0.8× 746 0.8× 1.1k 1.7× 499 1.0× 16 2.4k
Martina Auer Austria 18 1.5k 1.0× 925 0.8× 654 0.7× 851 1.4× 316 0.6× 26 2.1k
H. Tissing Netherlands 7 2.1k 1.4× 3.1k 2.6× 1.4k 1.5× 632 1.0× 253 0.5× 10 4.0k

Countries citing papers authored by AmirAli Talasaz

Since Specialization
Citations

This map shows the geographic impact of AmirAli Talasaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by AmirAli Talasaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites AmirAli Talasaz more than expected).

Fields of papers citing papers by AmirAli Talasaz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by AmirAli Talasaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by AmirAli Talasaz. The network helps show where AmirAli Talasaz may publish in the future.

Co-authorship network of co-authors of AmirAli Talasaz

This figure shows the co-authorship network connecting the top 25 collaborators of AmirAli Talasaz. A scholar is included among the top collaborators of AmirAli Talasaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with AmirAli Talasaz. AmirAli Talasaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sharif, Behnam, Gabriel Tremblay, Victoria M. Raymond, et al.. (2024). Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherence. Journal of Medical Economics. 27(1). 991–1002. 1 indexed citations
2.
Nassar, Amin H., Archana Agarwal, Rebecca J. Nagy, et al.. (2020). Genomic landscape of circulating tumor (ct)-DNA alterations in patients with penile cancer.. Journal of Clinical Oncology. 38(6_suppl). 6–6. 1 indexed citations
3.
Parikh, Aparna R., Genevieve M. Boland, Anna Hartwig, et al.. (2019). Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer. Annals of Oncology. 30. iv131–iv131. 2 indexed citations
4.
Cho, Jong Ho, Il-Jin Kim, Jung Hee Lee, et al.. (2019). Circulating tumor DNA (ctDNA) mutation and epigenomic patterns in early-stage lung cancer patients and its utility in identifying patients at high risk for early recurrence.. Journal of Clinical Oncology. 37(15_suppl). e14557–e14557. 1 indexed citations
5.
Zill, Oliver A., Kimberly C. Banks, Stephen R. Fairclough, et al.. (2018). The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clinical Cancer Research. 24(15). 3528–3538. 271 indexed citations breakdown →
6.
Odegaard, Justin I., John J. Vincent, Stefanie Mortimer, et al.. (2018). Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies. Clinical Cancer Research. 24(15). 3539–3549. 283 indexed citations
7.
Helman, Elena, Carlo G. Artieri, James V. Vowles, et al.. (2018). Abstract 5603: Analytical validation of a comprehensive 500-gene ctDNA panel designed for immuno-oncology and DNA damage research. Cancer Research. 78(13_Supplement). 5603–5603. 15 indexed citations
8.
Loree, Jonathan M., John H. Strickler, Allan Andresson Lima Pereira, et al.. (2018). Serial monitoring of ctDNA to highlight mutation profiles in colorectal cancer.. Journal of Clinical Oncology. 36(4_suppl). 641–641. 2 indexed citations
9.
Schwaederlé, Maria, Sandip Pravin Patel, Hatim Husain, et al.. (2017). Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clinical Cancer Research. 23(17). 5101–5111. 118 indexed citations
10.
Strickler, John H., Kimberly C. Banks, Rebecca J. Nagy, et al.. (2017). Blood-based genomic profiling of circulating cell-free tumor DNA (ctDNA) in 1397 patients (pts) with colorectal cancer (CRC).. Journal of Clinical Oncology. 35(4_suppl). 584–584. 3 indexed citations
11.
Grivas, Petros, Rebecca J. Nagy, Gregory R. Pond, et al.. (2017). Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy.. Journal of Clinical Oncology. 35(6_suppl). 334–334. 3 indexed citations
12.
Grivas, Petros, Rebecca J. Nagy, Gregory R. Pond, et al.. (2017). Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape.. Journal of Clinical Oncology. 35(15_suppl). 4534–4534. 2 indexed citations
13.
Lee, Jeeyun, Seung Tae Kim, Kyoung-Mee Kim, et al.. (2016). Cell-free DNA sequencing-guided therapy in a prospective clinical trial: NEXT-2 trial—A feasibility analysis.. Journal of Clinical Oncology. 34(15_suppl). 11534–11534. 4 indexed citations
14.
Mack, Philip C., Kimberly C. Banks, Oliver A. Zill, et al.. (2016). O.02: Plasma Next Generation Sequencing of Over 5,000 Advanced Non-Small Cell Lung Cancer Patients With Clinical Correlations. Journal of Thoracic Oncology. 11(10). S168–S169. 4 indexed citations
15.
Zill, Oliver A., Claire Greene, Dragan Sebisanovic, et al.. (2015). Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discovery. 5(10). 1040–1048. 202 indexed citations
16.
Morelli, Maria Pia, Michael J. Overman, Bryan K. Kee, et al.. (2015). Predictors of clonal evolution in metastatic colorectal cancer patients.. Journal of Clinical Oncology. 33(15_suppl). 3604–3604. 1 indexed citations
17.
Hoon, Dave S.�B., et al.. (2014). Identification of multiple informative genomic mutations by deep sequencing of circulating cell-free tumor DNA in plasma of metastatic melanoma patients.. Journal of Clinical Oncology. 32(15_suppl). 9018–9018. 3 indexed citations
18.
Talasaz, AmirAli, Patrik L. Ståhl, Henrik Persson, et al.. (2007). Conformational flexibility of a model protein upon immobilization on self‐assembled monolayers. Biotechnology and Bioengineering. 100(1). 19–27. 7 indexed citations
19.
Talasaz, AmirAli, Mohsen Nemat‐Gorgani, Yang Liu, et al.. (2006). Prediction of protein orientation upon immobilization on biological and nonbiological surfaces. Proceedings of the National Academy of Sciences. 103(40). 14773–14778. 55 indexed citations
20.
Talasaz, AmirAli, Yang Liu, Mostafa Ronaghi, & Ronald W. Davis. (2006). Modeling of the Bioactivated Nanopore Devices. PubMed. 2. 1830–1833. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giulia Siravegna Breakdown of academic impact, for papers by Javier García-Corbacho Breakdown of academic impact, for papers by Petros Nikolinakos Breakdown of academic impact, for papers by Jonathan C. M. Wan Breakdown of academic impact, for papers by Kert D. Sabbath Breakdown of academic impact, for papers by Evelyne Lopez‐Crapez Breakdown of academic impact, for papers by Peter Ulz Breakdown of academic impact, for papers by Betania Mahler‐Araujo Breakdown of academic impact, for papers by Martina Auer Breakdown of academic impact, for papers by H. Tissing
Rankless by CCL
2026